Treace Medical Concepts, Inc. revised earnings guidance for the full-year 2024. The company now expected full-year 2024 revenue of $201 million to $211 million, representing growth of 7% to 13%, compared to full-year 2023. This compares to previous guidance of $220 million to $225 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.875 USD | +2.17% | +13.86% | -53.92% |
29/05 | Treace Medical Concepts Insider Bought Shares Worth $253,475, According to a Recent SEC Filing | MT |
17/05 | North American Morning Briefing : The "Everything -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-53.92% | 364M | |
+75.69% | 12.57B | |
-24.68% | 7.34B | |
+6.22% | 6.61B | |
+12.58% | 5.39B | |
+26.90% | 4.53B | |
-21.14% | 3.91B | |
-22.99% | 2.91B | |
+47.42% | 2.37B | |
-0.37% | 2B |
- Stock Market
- Equities
- TMCI Stock
- News Treace Medical Concepts, Inc.
- Treace Medical Concepts, Inc. Revises Earnings Guidance for the Full-Year 2024